Metabolic & Weight

5-Amino-1MQ is a selective, membrane-permeable small-molecule NNMT inhibitor (EC50 ~2.3 µM in adipocytes) that blocks nicotinamide methylation to 1-MNA, preserving nicotinamide for NAD+ salvage, elevating NAD+ 1.2-1.6 fold, and activating Sirt1 for metabolic benefits including ~35% adipose reduction without appetite effects.

AOD-9604 is a 16-amino-acid C-terminal fragment (aa 177-191 + N-terminal Tyr) of human GH that retains lipolytic activity via β3-adrenergic receptor upregulation without growth-promoting, diabetogenic, or IGF-1-stimulating effects. Phase 2b obesity trials failed, but cartilage regeneration research continues.

GLP1-S is a GLP-1 receptor agonist peptide analog with 94% homology to human GLP-1. It is FDA-approved for type 2 diabetes and chronic weight management under various brand names. Research-grade glp1-s is studied separately from approved pharmaceutical products.

GLP2-T is an FDA-approved dual GIP/GLP-1 receptor agonist with imbalanced potency favoring GIPR (equal to native GIP) over GLP-1R (~5-fold weaker than native GLP-1). SURPASS trials showed HbA1c reductions of 1.8-2.4% and weight loss of 7-12 kg; SURMOUNT trials achieved 15-22.5% body weight reduction over 72 weeks.

GLP3-R is a first-in-class triple agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. Currently in multiple Phase 3 clinical trials (2024-2025) by Eli Lilly for obesity, type 2 diabetes, and related conditions, with Phase 2 data showing unprecedented 24.2% mean weight loss at 48 weeks.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the 12S rRNA gene of mitochondrial DNA. Discovered in 2015, it functions as an 'exercise mimetic' through AMPK activation, NAD+ elevation, and sirtuin activation, with levels declining approximately 21% in elderly populations and higher levels observed in centenarians.

Bioglutide is a first-in-class oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon. Phase 2 showed 13.8% weight loss with muscle preservation.

L-Carnitine is an FDA-approved amino acid derivative essential for fatty acid transport into mitochondria, with injectable form providing 100% bioavailability.

Mazdutide is a dual GLP-1 and glucagon receptor agonist in Phase 3 trials showing up to 14% weight loss and significant liver fat reduction in MASH studies.

Orforglipron is a novel oral non-peptide GLP-1 receptor agonist showing up to 14.7% weight loss, offering injectable-comparable efficacy without injections.

Survodutide is a dual glucagon and GLP-1 receptor agonist in Phase 3 trials for obesity and MASH/NASH, showing up to 19% weight loss and significant liver fat reduction.

Adipotide is a chimeric peptide that targets and destroys blood vessels feeding white adipose tissue, causing rapid fat loss through apoptosis of fat cells. Highly experimental with significant side effects.

Lipo-C is a lipotropic injection containing Methionine, Inositol, Choline (MIC), and B vitamins that support liver function and fat metabolism.

SLU-PP-332 is a synthetic 'exercise mimetic' that activates metabolic pathways engaged during physical exercise, showing 12% weight loss and 70% endurance increase in animal studies. NOT FOR HUMAN USE.

Tesofensine is a triple monoamine reuptake inhibitor showing up to 12.8% weight loss in trials, one of the most effective oral weight loss agents studied.

Fat Blaster is a lipotropic injection blend combining L-Carnitine, Methionine-Inositol-Choline (MIC), B vitamins, and NADH for enhanced fat metabolism support.

TRT (Testosterone Replacement Therapy) is FDA-approved for treating male hypogonadism, using testosterone cypionate or enanthate esters for sustained hormone levels.